市場調查報告書

復發性、難治性多發性骨髓瘤(RRMM)- 流行病學預測 2028年

Relapsing Refractory Multiple Myeloma - Epidemiology Forecast to 2028

出版商 DelveInsight Business Research LLP 商品編碼 911521
出版日期 內容資訊 英文 80 Pages
商品交期: 最快1-2個工作天內
價格
復發性、難治性多發性骨髓瘤(RRMM)- 流行病學預測 2028年 Relapsing Refractory Multiple Myeloma - Epidemiology Forecast to 2028
出版日期: 2019年09月01日內容資訊: 英文 80 Pages
簡介

本報告提供新興10個國家(土耳其,俄羅斯,沙烏地阿拉伯,阿拉伯聯合大公國,墨西哥,哥倫比亞,巴西,阿根廷,中國,台灣)的復發性、難治性多發性骨髓瘤(RRMM)市場調查,彙整市場及疾病概要,性別、選擇藥、各國流行病學的預測,市場成長要素及障礙分析等資料。

目錄

第1章 重要洞察

第2章 疾病背景和概要:復發性、難治性多發性骨髓瘤(RRMM)

  • 簡介
  • 症狀
  • 分子分類
  • 分期
  • 診斷
  • 病因
  • 病理生理學
  • 生物標記
  • 患者相關的危險因素
  • 復發性多發性骨髓瘤的治療方法的選擇的影響因素
  • 多發性骨髓瘤概要

第3章 流行病學和患者人口

  • 新興10個國家的復發性、難治性多發性骨髓瘤(RRMM)的患者人口

第4章 復發性、難治性多發性骨髓瘤(RRMM)的流行病學:各國

  • 東亞
    • 中國
      • 多發性骨髓瘤(MM)的診斷罹患數
      • 多發性骨髓瘤(MM)的診斷罹患數:性別
      • 多發性骨髓瘤(MM)的診斷罹患數(第二選擇藥)
      • 多發性骨髓瘤(MM)的診斷罹患數(第三選擇藥)
      • 復發性、難治性多發性骨髓瘤(RRMM)的診斷罹患數
    • 台灣
      • 多發性骨髓瘤(MM)的診斷罹患數
      • 多發性骨髓瘤(MM)的診斷罹患數:性別
      • 多發性骨髓瘤(MM)的診斷罹患數(第二選擇藥)
      • 多發性骨髓瘤(MM)的診斷罹患數(第三選擇藥)
      • 復發性、難治性多發性骨髓瘤(RRMM)的診斷罹患數
  • 中東
    • 沙烏地阿拉伯
      • 多發性骨髓瘤(MM)的診斷罹患數
      • 多發性骨髓瘤(MM)的診斷罹患數:性別
      • 多發性骨髓瘤(MM)的診斷罹患數(第二選擇藥)
      • 多發性骨髓瘤(MM)的診斷罹患數(第三選擇藥)
      • 復發性、難治性多發性骨髓瘤(RRMM)的診斷罹患數
    • 阿拉伯聯合大公國
      • 多發性骨髓瘤(MM)的診斷罹患數
      • 多發性骨髓瘤(MM)的診斷罹患數:性別
      • 多發性骨髓瘤(MM)的診斷罹患數(第二選擇藥)
      • 多發性骨髓瘤(MM)的診斷罹患數(第三選擇藥)
      • 復發性、難治性多發性骨髓瘤(RRMM)的診斷罹患數
  • 東歐
    • 俄羅斯
      • 多發性骨髓瘤(MM)的診斷罹患數
      • 多發性骨髓瘤(MM)的診斷罹患數:性別
      • 多發性骨髓瘤(MM)的診斷罹患數(第二選擇藥)
      • 多發性骨髓瘤(MM)的診斷罹患數(第三選擇藥)
      • 復發性、難治性多發性骨髓瘤(RRMM)的診斷罹患數
    • 土耳其
      • 多發性骨髓瘤(MM)的診斷罹患數
      • 多發性骨髓瘤(MM)的診斷罹患數:性別
      • 多發性骨髓瘤(MM)的診斷罹患數(第二選擇藥)
      • 多發性骨髓瘤(MM)的診斷罹患數(第三選擇藥)
      • 復發性、難治性多發性骨髓瘤(RRMM)的診斷罹患數
  • 南美
    • 墨西哥
      • 多發性骨髓瘤(MM)的診斷罹患數
      • 多發性骨髓瘤(MM)的診斷罹患數:性別
      • 多發性骨髓瘤(MM)的診斷罹患數(第二選擇藥)
      • 多發性骨髓瘤(MM)的診斷罹患數(第三選擇藥)
      • 復發性、難治性多發性骨髓瘤(RRMM)的診斷罹患數
    • 巴西
      • 多發性骨髓瘤(MM)的診斷罹患數
      • 多發性骨髓瘤(MM)的診斷罹患數:性別
      • 多發性骨髓瘤(MM)的診斷罹患數(第二選擇藥)
      • 多發性骨髓瘤(MM)的診斷罹患數(第三選擇藥)
      • 再復發性、難治性多發性骨髓瘤(RRMM)的診斷罹患數
    • 阿根廷
      • 多發性骨髓瘤(MM)的診斷罹患數
      • 多發性骨髓瘤(MM)的診斷罹患數:性別
      • 多發性骨髓瘤(MM)的診斷罹患數(第二選擇藥)
      • 多發性骨髓瘤(MM)的診斷罹患數(第三選擇藥)
      • 復發性、難治性多發性骨髓瘤(RRMM)的診斷罹患數
    • 哥倫比亞
      • 多發性骨髓瘤(MM)的診斷罹患數
      • 多發性骨髓瘤(MM)的診斷罹患數:性別
      • 多發性骨髓瘤(MM)的診斷罹患數(第二選擇藥)
      • 多發性骨髓瘤(MM)的診斷罹患數(第三選擇藥)
      • 復發性、難治性多發性骨髓瘤(RRMM)的診斷罹患數

第5章 市場成長要素

第6章 市場障礙

第7章 附錄

  • 報告方法

第8章 DelveInsight的服務內容

第9章 免責聲明

第10章 關於DelveInsight

目錄
Product Code: DIEI0385

DelveInsight's 'Relapsing Refractory Multiple Myeloma- Epidemiology Forecast to 2028' report delivers an in-depth understanding of the disease, historical & forecasted epidemiology of Relapsing Refractory Multiple Myeloma in Asia (China and Taiwan), Middle East (Saudi Arabia and UAE), Eastern Europe (Russia and Turkey) and LATAM (Mexico, Brazil, Argentina and Columbia).

Geography Covered

  • Asia (China and Taiwan)
  • Middle East (Saudi Arabia and UAE)
  • Eastern Europe (Russia and Turkey)
  • LATAM (Mexico, Brazil, Argentina and Columbia)

Study Period: 2017-2028

Relapsing Refractory Multiple Myeloma - Disease Understanding

Multiple Myeloma (MM) is the second most incident hematological malignancy worldwide, with a median onset of 60 years. This incurable malignancy develops from an accumulation of terminally differentiated monoclonal plasma cells (PC) in the bone marrow. The mechanism of action of MM characterized by the unusual increase of monoclonal paraprotein leading to evidence of specific end-organ damage. The majority of patients with multiple myeloma (MM) will have an initial response to treatment with modern combination regimens. However, conventional therapy is not curative and most of these patients will ultimately progress. In addition, some patients will not respond to initial treatment (i.e., refractory disease). Relapsed or refractory MM is usually identified through routine monitoring with laboratory studies. The signs and symptoms of Multiple Myeloma include hypercalcemia, renal insufficiency, anemia, lytic bony lesions along with a monoclonal protein in the serum, increase in the number of clonal plasma cells in the bone marrow, etc.

The DelveInsight Relapsing Refractory Multiple Myeloma market report gives the thorough understanding of the Relapsing Refractory Multiple Myeloma by including details such as disease introduction, symptoms of multiple myeloma, molecular classification of Multiple Myeloma, stages of multiple myeloma, pathogenesis, pathophysiology, biomarkers for multiple myeloma, diagnosis and patient-related risk factors.

Relapsing Refractory Multiple Myeloma Epidemiology

The Relapsing Refractory Multiple Myeloma epidemiology division provide the insights about historical and current patient pool and forecasted trend for every 10 major emerging markets (EM). The epidemiology data for Relapsing Refractory Multiple Myeloma are studied through all possible division to give a better understanding about the disease scenario in 10 EM. It also helps to recognize the causes of current and forecasted trends by exploring numerous studies, survey reports and views of key opinion leaders.

Relapsing Refractory Multiple Myeloma Epidemiology

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology scenario of Relapsing Refractory Multiple Myeloma in 10 EM covering Asia (China and Taiwan), Middle East (Saudi Arabia and UAE), Eastern Europe (Russia and Turkey) and LATAM (Mexico, Brazil, Argentina and Columbia) from 2017-2028 for the following aspects:

  • Diagnosed Incident cases of Multiple Myeloma (MM)
  • Gender-specific Diagnosed Incidence of Multiple Myeloma (MM)
  • Diagnosed Incident Multiple Myeloma (MM) Population on Second Line of Treatment
  • Diagnosed Incident Multiple Myeloma (MM) Population on Third Line (and above) of Treatment
  • Total Diagnosed Incident RRMM cases

There are several potential research papers and studies evaluated in order to analyze the overall epidemiology trend in the emerging markets. Few are listed below:

Lu et al. conducted a study "Clinical features and treatment outcome in newly diagnosed Chinese patients with multiple myeloma: results of a multicenter analysis" with the aim to understand the clinical features and treatment outcome of Chinese patients with multiple myeloma (MM). As per the study, if the Japanese incidence of MM is applied to China, there would be an estimated 27,800 new cases (1.39 billion × 2 per 100,000) each year and a total of 200,000 cases in China. With the acceleration of the aging process in China, it is predicted that MM, with rapid growth in incidence, will become one of the more significant diseases that affect people's health in the country. It has also been reported that immigrants from Asia living in the USA have an increased incidence of MM compared with those living in Asia.

Hungria et al. suggest that Multiple Myeloma (MM) is a disorder characterized by abnormal clonal proliferation of plasmocytes in the bone marrow resulting in the production of monoclonal immunoglobulins associated with organic disorders. MM accounts for 1% of all neoplastic diseases and 13% of hematologic neoplasms as stated in "Guidelines on the diagnosis and management of multiple myeloma treatment: Associacao Brasileira de Hematologia e Hemoterapia e Terapia Celular Project guidelines: Associacao Medica Brasileira - 2012." In Brazil, there is no exact knowledge of the incidence of this disease.

Report Scope

  • The report covers detailed overview of Relapsing Refractory Multiple Myeloma explaining its causes, symptoms, and classification, pathophysiology, diagnosis and treatment patterns.
  • The report provides the insight about the historical and forecasted patient pool for 10 emerging markets covering Asia (China and Taiwan), Middle East (Saudi Arabia and UAE), Eastern Europe (Russia and Turkey) and LATAM (Mexico, Brazil, Argentina and Columbia).
  • The Report assesses the disease risk and burden and highlights the unmet needs of Relapsing Refractory Multiple Myeloma.
  • The Report helps to recognize the growth opportunities in 10 EM with respect to the patient population.
  • The report provides the segmentation of the disease epidemiology by type specific cases and severity specific cases of Relapsing Refractory Multiple Myeloma in 10 EM.

Key strengths

  • 10 Year Forecast of Relapsing Refractory Multiple Myeloma epidemiology
  • 10 EM Coverage
  • Total Incident Cases of Relapsing Refractory Multiple Myeloma
  • Incident Cases according to segmentation

Key assessments

  • Patient Segmentation
  • Disease Risk & Burden
  • Risk of disease by the segmentation
  • Factors driving growth in a specific patient population

Table of Contents

1. Key Insights

2. Disease Background and Overview: Relapsing Refractory Multiple Myeloma (RRMM)

  • 2.1. Introduction
  • 2.2. Symptoms of multiple myeloma
  • 2.3. Molecular Classification of Multiple Myeloma
  • 2.4. Stages of Multiple Myeloma
  • 2.5. Diagnosis of Multiple Myeloma
  • 2.6. Pathogenesis of Multiple Myeloma
    • 2.6.1. Molecular mechanisms underlying the progression of multiple myeloma
    • 2.6.2. Molecular pathogenesis of multiple myeloma and its premalignant precursor
  • 2.7. Pathophysiology of Multiple Myeloma
  • 2.8. Biomarkers for Multiple Myeloma
    • 2.8.1. Serum M-protein and light chains as biomarkers
    • 2.8.2. Potential proteomic biomarkers
    • 2.8.3. Cytogenetic biomarkers in multiple myeloma
  • 2.9. Patient-related risk factors
  • 2.10. Factors influencing the choice of therapy at relapse
  • 2.11. Nutshell of Multiple Myeloma

3. Epidemiology and Patient Population: Key Findings

  • 3.1. 10 EM Total Diagnosed Incident Patient Population of Relapsing Refractory Multiple Myeloma

4. Country Wise-Epidemiology of Relapsing Refractory Multiple Myeloma

  • 4.1. East Asia: China and Taiwan
    • 4.1.1. Assumptions and Rationale
  • 4.2. China
    • 4.2.1. Multiple Myeloma (MM) Diagnosed Incident cases in China
    • 4.2.2. Multiple Myeloma (MM) Gender-specific Diagnosed Incidence in China
    • 4.2.3. Multiple Myeloma (MM) Diagnosed Incident Population on Second Line of Treatment in China
    • 4.2.4. Multiple Myeloma (MM) Diagnosed Incident Population on Third Line (and above) of Treatment in China
    • 4.2.5. RRMM Total Diagnosed Incident cases in China
  • 4.3. Taiwan
    • 4.3.1. Multiple Myeloma (MM) Diagnosed Incident cases in Taiwan
    • 4.3.2. Multiple Myeloma (MM) Gender-specific Diagnosed Incidence in Taiwan
    • 4.3.3. Multiple Myeloma (MM) Diagnosed Incident Population on Second Line of Treatment in Taiwan
    • 4.3.4. Multiple Myeloma (MM) Diagnosed Incident Population on Third Line (and above) of Treatment in Taiwan
    • 4.3.5. RRMM Total Diagnosed Incident cases in Taiwan
  • 4.4. Middle East: Saudi Arabia and United Arab Emirates
    • 4.4.1. Assumptions and Rationale
  • 4.5. Saudi Arabia
    • 4.5.1. Multiple Myeloma (MM) Diagnosed Incident cases in Saudi Arabia
    • 4.5.2. Multiple Myeloma (MM) Gender-specific Diagnosed Incidence in Saudi Arabia
    • 4.5.3. Multiple Myeloma (MM) Diagnosed Incident Population on Second Line of Treatment in Saudi Arabia
    • 4.5.4. Multiple Myeloma (MM) Diagnosed Incident Population on Third Line (and above) of Treatment in Saudi Arabia
    • 4.5.5. RRMM Total Diagnosed Incident cases in Saudi Arabia
  • 4.6. United Arab Emirates
    • 4.6.1. Multiple Myeloma (MM) Diagnosed Incident cases in United Arab Emirates
    • 4.6.2. Multiple Myeloma (MM) Gender-specific Diagnosed Incidence in United Arab Emirates
    • 4.6.3. Multiple Myeloma (MM) Diagnosed Incident Population on Second Line of Treatment in United Arab Emirates
    • 4.6.4. Multiple Myeloma (MM) Diagnosed Incident Population on Third Line (and above) of Treatment in United Arab Emirates
    • 4.6.5. RRMM Total Diagnosed Incident cases in United Arab Emirates
  • 4.7. Eastern Europe: Russia and Turkey
    • 4.7.1. Assumptions and Rationale
  • 4.8. Russia
    • 4.8.1. Multiple Myeloma (MM) Diagnosed Incident cases in Russia
    • 4.8.2. Multiple Myeloma (MM) Gender-specific Diagnosed Incidence in Russia
    • 4.8.3. Multiple Myeloma (MM) Diagnosed Incident Population on Second Line of Treatment in Russia
    • 4.8.4. Multiple Myeloma (MM) Diagnosed Incident Population on Third Line (and above) of Treatment in Russia
    • 4.8.5. RRMM Total Diagnosed Incident cases in Russia
  • 4.9. Turkey
    • 4.9.1. Multiple Myeloma (MM) Diagnosed Incident cases in Turkey
    • 4.9.2. Multiple Myeloma (MM) Gender-specific Diagnosed Incidence in Turkey
    • 4.9.3. Multiple Myeloma (MM) Diagnosed Incident Population on Second Line of Treatment in Turkey
    • 4.9.4. Multiple Myeloma (MM) Diagnosed Incident Population on Third Line (and above) of Treatment in Turkey
    • 4.9.5. RRMM Total Diagnosed Incident cases in Turkey
  • 4.10. Latin America (LATAM): Argentina, Brazil, Colombia, Mexico
    • 4.10.1. Assumptions and Rationale
  • 4.11. Mexico
    • 4.11.1. Multiple Myeloma (MM) Diagnosed Incident cases in Mexico
    • 4.11.2. Multiple Myeloma (MM) Gender-specific Diagnosed Incidence in Mexico
    • 4.11.3. Multiple Myeloma (MM) Diagnosed Incident Population on Second Line of Treatment in Mexico
    • 4.11.4. Multiple Myeloma (MM) Diagnosed Incident Population on Third Line (and above) of Treatment in Mexico
    • 4.11.5. RRMM Total Diagnosed Incident cases in Mexico
  • 4.12. Brazil
    • 4.12.1. Multiple Myeloma (MM) Diagnosed Incident cases in Brazil
    • 4.12.2. Multiple Myeloma (MM) Gender-specific Diagnosed Incidence in Brazil
    • 4.12.3. Multiple Myeloma (MM) Diagnosed Incident Population on Second Line of Treatment in Brazil
    • 4.12.4. Multiple Myeloma (MM) Diagnosed Incident Population on Third Line (and above) of Treatment in Brazil
    • 4.12.5. RRMM Total Diagnosed Incident cases in Brazil
  • 4.13. Argentina
    • 4.13.1. Multiple Myeloma (MM) Diagnosed Incident cases in Argentina
    • 4.13.2. Multiple Myeloma (MM) Gender-specific Diagnosed Incidence in Argentina
    • 4.13.3. Multiple Myeloma (MM) Diagnosed Incident Population on Second Line of Treatment in Argentina
    • 4.13.4. Multiple Myeloma (MM) Diagnosed Incident Population on Third Line (and above) of Treatment in Argentina
    • 4.13.5. RRMM Total Diagnosed Incident cases in Argentina
  • 4.14. Colombia
    • 4.14.1. Multiple Myeloma (MM) Diagnosed Incident cases in Colombia
    • 4.14.2. Multiple Myeloma (MM) Gender-specific Diagnosed Incidence in Colombia
    • 4.14.3. Multiple Myeloma (MM) Diagnosed Incident Population on Second Line of Treatment in Colombia
    • 4.14.4. Multiple Myeloma (MM) Diagnosed Incident Population on Third Line (and above) of Treatment in Colombia
    • 4.14.5. RRMM Total Diagnosed Incident cases in Colombia

5. Market Drivers

6. Market Barriers

7. Appendix

  • 7.1. Report Methodology

8. DelveInsight Capabilities

9. Disclaimer

10. About DelveInsight

List of Tables

Table 1 Total Diagnosed Incident Patient Population of Relapsing Refractory Multiple Myeloma in 10 EM Countries (2017-2028)

Table 2 Multiple Myeloma (MM) Diagnosed Incident cases in China (2017-2028)

Table 3 Multiple Myeloma (MM) Gender-specific Diagnosed Incidence in China (2017-2028)

Table 4 Multiple Myeloma (MM) Diagnosed Incident Population on Second Line of Treatment in China (2017-2028)

Table 5 Multiple Myeloma (MM) Diagnosed Incident Population on Third Line (and above) of Treatment in China (2017-2028)

Table 6 RRMM Total Diagnosed Incident cases in China (2017-2028)

Table 7 Multiple Myeloma (MM) Diagnosed Incident cases in Taiwan (2017-2028)

Table 8 Multiple Myeloma (MM) Gender-specific Diagnosed Incidence in Taiwan (2017-2028)

Table 9 Multiple Myeloma (MM) Diagnosed Incident Population on Second Line of Treatment in Taiwan (2017-2028)

Table 10 Multiple Myeloma (MM) Diagnosed Incident Population on Third Line (and above) of Treatment in Taiwan (2017-2028)

Table 11 RRMM Total Diagnosed Incident cases in Taiwan (2017-2028)

Table 12 Multiple Myeloma (MM) Diagnosed Incident cases in Saudi Arabia (2017-2028)

Table 13 Multiple Myeloma (MM) Gender-specific Diagnosed Incidence in Saudi Arabia (2017-2028)

Table 14 Multiple Myeloma (MM) Diagnosed Incident Population on Second Line of Treatment in Saudi Arabia (2017-2028)

Table 15 Multiple Myeloma (MM) Diagnosed Incident Population on Third Line (and above) of Treatment in Saudi Arabia (2017-2028)

Table 16 RRMM Total Diagnosed Incident cases in Saudi Arabia (2017-2028)

Table 17 Multiple Myeloma (MM) Diagnosed Incident cases in United Arab Emirates (2017-2028)

Table 18 Multiple Myeloma (MM) Gender-specific Diagnosed Incidence in United Arab Emirates (2017-2028)

Table 19 Multiple Myeloma (MM) Diagnosed Incident Population on Second Line of Treatment in United Arab Emirates (2017-2028)

Table 20 Multiple Myeloma (MM) Diagnosed Incident Population on Third Line (and above) of Treatment in United Arab Emirates (2017-2028)

Table 21 RRMM Total Diagnosed Incident cases in United Arab Emirates (2017-2028)

Table 22 Multiple Myeloma (MM) Diagnosed Incident cases in Russia (2017-2028)

Table 23 Multiple Myeloma (MM) Gender-specific Diagnosed Incidence in Russia (2017-2028)

Table 24 Multiple Myeloma (MM) Diagnosed Incident Population on Second Line of Treatment in Russia (2017-2028)

Table 25 8 Multiple Myeloma (MM) Diagnosed Incident Population on Third Line (and above) of Treatment in Russia (2017-2028)

Table 26 RRMM Total Diagnosed Incident cases in Russia (2017-2028)

Table 27 Multiple Myeloma (MM) Diagnosed Incident cases in Turkey (2017-2028)

Table 28 Multiple Myeloma (MM) Gender-specific Diagnosed Incidence in Turkey (2017-2028)

Table 29 Multiple Myeloma (MM) Diagnosed Incident Population on Second Line of Treatment in Turkey (2017-2028)

Table 30 Multiple Myeloma (MM) Diagnosed Incident Population on Third Line (and above) of Treatment in Turkey (2017-2028)

Table 31 RRMM Total Diagnosed Incident cases in Turkey (2017-2028)

Table 32 Multiple Myeloma (MM) Diagnosed Incident cases in Mexico (2017-2028)

Table 33 Multiple Myeloma (MM) Gender-specific Diagnosed Incidence in Mexico (2017-2028)

Table 34 Multiple Myeloma (MM) Diagnosed Incident Population on Second Line of Treatment in Mexico (2017-2028)

Table 35 Multiple Myeloma (MM) Diagnosed Incident Population on Third Line (and above) of Treatment in Mexico (2017-2028)

Table 36 RRMM Total Diagnosed Incident cases in Turkey in Mexico (2017-2028)

Table 37 Multiple Myeloma (MM) Diagnosed Incident cases in Brazil (2017-2028)

Table 38 Multiple Myeloma (MM) Gender-specific Diagnosed Incidence in Brazil (2017-2028)

Table 39 Multiple Myeloma (MM) Diagnosed Incident Population on Second Line of Treatment in Brazil (2017-2028)

Table 40 Multiple Myeloma (MM) Diagnosed Incident Population on Third Line (and above) of Treatment in Brazil (2017-2028)

Table 41 RRMM Total Diagnosed Incident cases in Brazil (2017-2028)

Table 42 Multiple Myeloma (MM) Diagnosed Incident cases in Argentina (2017-2028)

Table 43 Multiple Myeloma (MM) Gender-specific Diagnosed Incidence in Argentina (2017-2028)

Table 44 Multiple Myeloma (MM) Diagnosed Incident Population on Second Line of Treatment in Argentina (2017-2028)

Table 45 Multiple Myeloma (MM) Diagnosed Incident Population on Third Line (and above) of Treatment in Argentina (2017-2028)

Table 46 RRMM Total Diagnosed Incident cases in Argentina (2017-2028)

Table 47 Multiple Myeloma (MM) Diagnosed Incident cases in Colombia (2017-2028)

Table 48 Multiple Myeloma (MM) Gender-specific Diagnosed Incidence in Colombia (2017-2028)

Table 49 Multiple Myeloma (MM) Diagnosed Incident Population on Second Line of Treatment in Colombia (2017-2028)

Table 50 Multiple Myeloma (MM) Diagnosed Incident Population on Third Line (and above) of Treatment in Colombia (2017-2028)

Table 51 RRMM Total Diagnosed Incident cases in Colombia (2017-2028)

List of Figures

Figure 1 Total Diagnosed Incident Patient Population of Relapsing Refractory Multiple Myeloma in 10 EM Countries (2017-2028)

Figure 2 Multiple Myeloma (MM) Diagnosed Incident cases in China (2017-2028)

Figure 3 Multiple Myeloma (MM) Gender-specific Diagnosed Incidence in China (2017-2028)

Figure 4 Multiple Myeloma (MM) Diagnosed Incident Population on Second Line of Treatment in China (2017-2028)

Figure 5 Multiple Myeloma (MM) Diagnosed Incident Population on Third Line (and above) of Treatment in China (2017-2028)

Figure 6 RRMM Total Diagnosed Incident cases in China (2017-2028)

Figure 7 Multiple Myeloma (MM) Diagnosed Incident cases in Taiwan (2017-2028)

Figure 8 Multiple Myeloma (MM) Gender-specific Diagnosed Incidence in Taiwan (2017-2028)

Figure 9 Multiple Myeloma (MM) Diagnosed Incident Population on Second Line of Treatment in Taiwan (2017-2028)

Figure 10 Multiple Myeloma (MM) Diagnosed Incident Population on Third Line (and above) of Treatment in Taiwan (2017-2028)

Figure 11 RRMM Total Diagnosed Incident cases in Taiwan (2017-2028)

Figure 12 Multiple Myeloma (MM) Diagnosed Incident cases in Saudi Arabia (2017-2028)

Figure 13 Multiple Myeloma (MM) Gender-specific Diagnosed Incidence in Saudi Arabia (2017-2028)

Figure 14 Multiple Myeloma (MM) Diagnosed Incident Population on Second Line of Treatment in Saudi Arabia (2017-2028)

Figure 15 Multiple Myeloma (MM) Diagnosed Incident Population on Third Line (and above) of Treatment in Saudi Arabia (2017-2028)

Figure 16 RRMM Total Diagnosed Incident cases in Saudi Arabia (2017-2028)

Figure 17 Multiple Myeloma (MM) Diagnosed Incident cases in United Arab Emirates (2017-2028)

Figure 18 Multiple Myeloma (MM) Gender-specific Diagnosed Incidence in United Arab Emirates (2017-2028)

Figure 19 Multiple Myeloma (MM) Diagnosed Incident Population on Second Line of Treatment in United Arab Emirates (2017-2028)

Figure 20 Multiple Myeloma (MM) Diagnosed Incident Population on Third Line (and above) of Treatment in United Arab Emirates (2017-2028)

Figure 21 RRMM Total Diagnosed Incident cases in United Arab Emirates (2017-2028)

Figure 22 Multiple Myeloma (MM) Diagnosed Incident cases in Russia (2017-2028)

Figure 23 Multiple Myeloma (MM) Gender-specific Diagnosed Incidence in Russia (2017-2028)

Figure 24 Multiple Myeloma (MM) Diagnosed Incident Population on Second Line of Treatment in Russia (2017-2028)

Figure 25 Multiple Myeloma (MM) Diagnosed Incident Population on Third Line (and above) of Treatment in Russia (2017-2028)

Figure 26 RRMM Total Diagnosed Incident cases in Russia (2017-2028)

Figure 27 Multiple Myeloma (MM) Diagnosed Incident cases in Turkey (2017-2028)

Figure 28 Multiple Myeloma (MM) Gender-specific Diagnosed Incidence in Turkey (2017-2028)

Figure 29 Multiple Myeloma (MM) Diagnosed Incident Population on Second Line of Treatment in Turkey (2017-2028)

Figure 30 Multiple Myeloma (MM) Diagnosed Incident Population on Third Line (and above) of Treatment in Turkey (2017-2028)

Figure 31 RRMM Total Diagnosed Incident cases in Turkey (2017-2028)

Figure 32 Multiple Myeloma (MM) Diagnosed Incident cases in Mexico (2017-2028)

Figure 33 Multiple Myeloma (MM) Gender-specific Diagnosed Incidence in Mexico (2017-2028)

Figure 34 Multiple Myeloma (MM) Diagnosed Incident Population on Second Line of Treatment in Mexico (2017-2028)

Figure 35 Multiple Myeloma (MM) Diagnosed Incident Population on Third Line (and above) of Treatment in Mexico (2017-2028)

Figure 36 RRMM Total Diagnosed Incident cases in Turkey in Mexico (2017-2028)

Figure 37 Multiple Myeloma (MM) Diagnosed Incident cases in Brazil (2017-2028)

Figure 38 Multiple Myeloma (MM) Gender-specific Diagnosed Incidence in Brazil (2017-2028)

Figure 39 Multiple Myeloma (MM) Diagnosed Incident Population on Second Line of Treatment in Brazil (2017-2028)

Figure 40 Multiple Myeloma (MM) Diagnosed Incident Population on Third Line (and above) of Treatment in Brazil (2017-2028)

Figure 41 RRMM Total Diagnosed Incident cases in Brazil (2017-2028)

Figure 42 Multiple Myeloma (MM) Diagnosed Incident cases in Argentina (2017-2028)

Figure 43 Multiple Myeloma (MM) Gender-specific Diagnosed Incidence in Argentina (2017-2028)

Figure 44 Multiple Myeloma (MM) Diagnosed Incident Population on Second Line of Treatment in Argentina (2017-2028)

Figure 45 Multiple Myeloma (MM) Diagnosed Incident Population on Third Line (and above) of Treatment in Argentina (2017-2028)

Figure 46 RRMM Total Diagnosed Incident cases in Argentina (2017-2028)

Figure 47 Multiple Myeloma (MM) Diagnosed Incident cases in Colombia (2017-2028)

Figure 48 Multiple Myeloma (MM) Gender-specific Diagnosed Incidence in Colombia (2017-2028)

Figure 49 Multiple Myeloma (MM) Diagnosed Incident Population on Second Line of Treatment in Colombia (2017-2028)

Figure 50 Multiple Myeloma (MM) Diagnosed Incident Population on Third Line (and above) of Treatment in Colombia (2017-2028)

Figure 51 RRMM Total Diagnosed Incident cases in Colombia (2017-2028)